Search clinical trials for: alirocumab

Total 93 results

Fundación Hipercolesterolemia Familiar

Completed

Alirocumab and Plaque Burden In Familial Hypercholesterolaemia (ARCHITECT)

Familial Hypercholesterolemia

Spain
Westside Medical Associates of Los Angeles
Regeneron Pharmaceuticals; University of Washington

Unknown

Assessment of Atherosclerotic Plaque Characteristics Change by DCE-MRI With Alirocumab

Atherosclerosis | Hyperlipidemia

United States
Population Health Research Institute

Completed

Effects of Acute, Rapid Lowering of LDL Cholesterol With Alirocumab in Patients With STEMI Undergoing Primary PCI (EPIC STEMI)

ST Elevation Myocardial Infarction | Dyslipidemias | Hypercholesterolemia | Hyperlipidemias | Acute Coronary Syndrome | Physiological Effects of Drugs

Canada
Shanghai Tong Ren Hospital
China Cardiovascular Association

Recruiting

Impact of Early PCSK9 Inhibitor Treatment on Heart After Acute Myocardium Infarction

Acute Myocardial Infarction

China
Regeneron Pharmaceuticals
Sanofi

Completed

Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo

Hypercholesterolemia

United States, Bulgaria, Chile, Estonia, Japan, Mexico, Russian Federation, South Africa, Ukraine
University of Virginia
Northwestern University

Completed

A Trial of Alirocumab and Plaque Regression in Peripheral Arterial Disease

Peripheral Arterial Disease

United States
Regeneron Pharmaceuticals
Sanofi

Terminated

Long Term Safety Study of PRALUENT

Heterozygous Familial Hypercholesterolemia | Non-familial Hypercholesterolemia

United States, Bulgaria, Estonia, Russian Federation, South Africa, Ukraine
Washington University School of Medicine

Completed

Alirocumab and Reverse Cholesterol Transport

Atherosclerosis | Coronary Heart Disease

United States
University Hospital Inselspital, Berne
Regeneron Pharmaceuticals

Completed

Vascular Effects of Alirocumab in Acute MI-Patients (PACMAN-AMI)

Coronary Circulation | Atheroma; Myocardial | Coronary Vessel

Denmark, Switzerland, Austria, Netherlands
Regeneron Pharmaceuticals
Sanofi

Completed

Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy (ODYSSEY ESCAPE)

Heterozygous Familial Hypercholesterolemia

United States, Germany
Regeneron Pharmaceuticals
Sanofi

Terminated

Praluent® (Alirocumab) Pregnancy Exposure Registry: An OTIS Pregnancy Surveillance Study

Hypercholesterolemia

United States
Regeneron Pharmaceuticals
Sanofi

Completed

A Study of Alirocumab in Participants With Autosomal Dominant Hypercholesterolemia (ADH) and Gain-of-Function Mutations (GOFm) of the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene or Loss-of-Function Mutations (LOFm) of the Apolipoprotein (Apo) B Gene

Hypercholesterolemia

France, United States
Regeneron Pharmaceuticals
Sanofi

Completed

Open-Label Extension of Study R727-CL-1003 (NCT01266876) to Evaluate the Long-Term Safety and Efficacy of Alirocumab (REGN727) in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)

Hypercholesterolemia | Heterozygous Familial Hypercholesterolemia

United States, Canada
Regeneron Pharmaceuticals
Sanofi

Completed

Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH) (ODYSSEY HoFH)

Homozygous Familial Hypercholesterolemia

United States, South Africa, Canada, Greece, Japan, Ukraine, Austria, Czechia, France, Germany, Italy, Taiwan, Turkey
Kobe University

Recruiting

To Evaluate the Efficacy of Alirocumab for Neoatherosclerosis by Using OCT, in Comparison With Standard Statin Therapy (POLARIS)

Coronary Artery Disease Progression

Japan
Kobe University

Unknown

The Efficacy of Alirocumab for Thin-cap fIbroatheroma in Patients With Coronary Artery Disease Estimated by Optical Coherence Tomography (ALTAIR)

Coronary Artery Disease | Thin-cap fIbroatheroma

Japan
Sanofi
Regeneron Pharmaceuticals

Completed

Pharmacokinetic of Alirocumab SAR236553 (REGN727) Administered Subcutaneously at 3 Different Injection Sites in Healthy Subjects

Hypercholesterolemia

United Kingdom
Nantes University Hospital
Regeneron Pharmaceuticals

Completed

Effect of Alirocumab on Postprandial Hyperlipemia in Patients With Type 2 Diabetes (EUTERPE)

Type2 Diabetes

France
Regeneron Pharmaceuticals
Sanofi

Completed

Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)

Hypercholesterolemia

United States, Bulgaria, Canada, Norway, Israel, Slovakia, United Kingdom, Hungary
Sanofi
Regeneron Pharmaceuticals

Completed

Pharmacokinetic and Tolerability of Alirocumab SAR236553 (REGN727) in Patients With Hepatic Impairment and in Healthy Subjects

Hypercholesterolemia

Moldova, Republic of, France
Sanofi
Regeneron Pharmaceuticals

Completed

Injection Site Tolerability, Safety, Pharmacokinetics, Pharmacodynamics in Different Single-Dose Treatments of Alirocumab SAR236553 (REGN727) in Healthy Subjects

Hypercholesterolemia

United States
Sanofi
Regeneron Pharmaceuticals

Completed

Study of the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of Alirocumab SAR236553 (REGN727)

Hypercholesterolemia

United States
Sanofi
Regeneron Pharmaceuticals

Completed

Ascending Dose Study of the Safety and Tolerability of Alirocumab (SAR236553/REGN727) in Japanese Healthy Volunteers

Hypercholesterolemia

Japan
University of Utah
Regeneron Pharmaceuticals

Terminated

PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis (PINNACLE)

Stroke | Intracranial Atherosclerosis | Intraplaque Hemorrhage

United States
Virginia Commonwealth University
Sanofi; Regeneron Pharmaceuticals

Completed

Alirocumab in Patients With Acute Myocardial Infarction

Myocardial Infarction | Hypercholesterolemia

United States
Regeneron Pharmaceuticals
Sanofi

Completed

Study of the Safety and Efficacy of REGN727/SAR236553 in Patients With HeFH Hypercholesterolemia

Hypercholesterolemia

United States, Canada
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN)

Hypercholesterolemia

Japan
Sanofi
Regeneron Pharmaceuticals

Completed

A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous (SC) Administered Alirocumab in Healthy Chinese Subjects

Hypercholesterolemia

China
Sanofi
Regeneron Pharmaceuticals

Completed

Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan

Hypercholesterolemia

Korea, Republic of, Taiwan
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)

Hypercholesterolemia

United States
Sanofi
Regeneron Pharmaceuticals

Completed

Effect of Alirocumab on Lipid Metabolism in Adults With Elevated LDL-Cholesterol

Hypercholesterolemia

United States
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)

Hypercholesterolaemia

Netherlands, United States, Canada, Russian Federation, South Africa
Sanofi
Regeneron Pharmaceuticals

Completed

Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)

Hypercholesterolemia

Sweden, Germany, Russian Federation, Denmark, Israel, South Africa, Spain, Hungary, United States, Colombia, Czech Republic, Argentina, Belgium, Bulgaria, Canada, Chile, Finland, France, Italy, Mexico, Netherlands, Norway, Poland, Por... and more
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy (ODYSSEY FH I)

Hypercholesterolemia

United States, Austria, Canada, Czech Republic, Denmark, France, Israel, Netherlands, Norway, Russian Federation, South Africa, Spain, Sweden, United Kingdom
Wolfson Medical Center
Sanofi; Assaf-Harofeh Medical Center

Unknown

Treatment of Severe Infection With Antihyperlipidemia Drug

Sepsis | Septic Shock

Israel
Sanofi
Regeneron Pharmaceuticals

Completed

Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)

Hypercholesterolemia

United States, Australia, Belgium, Canada, Denmark, Netherlands, New Zealand, Spain
Sanofi
Regeneron Pharmaceuticals

Completed

ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

Atherosclerotic Cardiovascular Disease

China, Hong Kong, Austria, Bulgaria, Norway, Peru, France, Japan, Spain, Lithuania, Philippines, Israel, Belgium, Croatia, Poland, Hungary, Chile, Mexico, Latvia, Singapore, Switzerland, Colombia, Greece, Ukraine, Turkey, Finland, United States and more
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia (ODYSSEY MONO)

Hypercholesterolemia

United States, Belgium, Finland, Netherlands
Stanford University
National Heart, Lung, and Blood Institute (NHLBI)

Enrolling by invitation

PCSK9 Inhibition After Heart Transplantation

Vasculopathy

United States
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy in Japan

Hypercholesterolemia

Japan
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy

Hypercholesterolemia

United States
Sanofi
Regeneron Pharmaceuticals

Completed

Open Label Study of Long Term Safety Evaluation of Alirocumab (ODYSSEY OLE)

Hypercholesterolemia

United States, Argentina, Austria, Belgium, Bulgaria, Canada, Czechia, Denmark, Finland, France, Germany, Hungary, Israel, Italy, Mexico, Netherlands, Norway, Portugal, Romania, Russian Federation, South Africa, Spain, Sweden, United...
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)

Hypercholesterolemia

United States, Canada, Denmark, France, Hungary, Israel, Korea, Republic of, Russian Federation, South Africa, Ukraine
Federico II University

Recruiting

Evaluation of Adherence, Persistence and Efficacy of Treatment With PCSK9 Inhibitors in Italy (AT-TARGET-IT)

Hypercholesterolemia

Italy
Shanghai Tong Ren Hospital

Recruiting

Impact of Early PCSK9 Inhibitor on Heart After Acute Myocardium Infarction (PERFECT-AMI)

Early PCSK9 Inhibitor on Ventricular Remodling

China
Gloria Vega
Regeneron Pharmaceuticals; Aventis Pharmaceuticals

Terminated

Effect of PCSK9-Antibody (Alirocumab) on Dyslipidemia Secondary to Nephrotic Syndrome

Nephrotic Syndrome

United States
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) When Co-administered With High Dose of Atorvastatin in Patients With Primary Hypercholesterolemia

Hypercholesterolemia

United States
Baylor Research Institute
Regeneron Pharmaceuticals

Unknown

Alirocumab in Patients on a Stable Dialysis Regimen

Hemodialysis | Peritoneal Dialysis | Hypercholesterolemia | Atherosclerotic Disease

United States
Sanofi
Regeneron Pharmaceuticals

Completed

Injection Site Tolerability, Safety, Pharmacokinetics and Pharmacodynamics Study After a Single Dose Subcutaneous Treatment of Alirocumab SAR236553 (REGN727)

Hypercholesterolemia

United States
Duke University
Regeneron Pharmaceuticals

Recruiting

PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung

Non-small Cell Lung Cancer (NSCLC)

United States

Search clinical trials for: alirocumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Taiwan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations